Verona Pharma (LON:VRP) posted its earnings results on Tuesday. The company reported GBX (23.40) (($0.32)) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of GBX (26.10) (($0.36)) by GBX 2.70 ($0.04), Digital Look Earnings reports.
Shares of Verona Pharma (VRP) opened at GBX 137.44 ($1.90) on Tuesday. Verona Pharma has a 52-week low of GBX 100 ($1.38) and a 52-week high of GBX 189 ($2.61).
In related news, insider David Ebsworth acquired 10,000 shares of the stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average price of GBX 107 ($1.48) per share, for a total transaction of £10,700 ($14,783.09).
Verona Pharma Company Profile
Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.